<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cytokines and inflammation</journal-id><journal-title-group><journal-title xml:lang="en">Cytokines and inflammation</journal-title><trans-title-group xml:lang="ru"><trans-title>Цитокины и воспаление</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1684-7849</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">623115</article-id><article-id pub-id-type="doi">10.17816/CI2022221-4-10</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Features of innate and adaptive immunity in patients with moderate course of COVID-19 with various degrees of lung tissue damage</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности врожденного и адаптивного иммунитета у пациентов со среднетяжелым течением COVID-19 при различных степенях поражения легочной ткани</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0165-6805</contrib-id><name-alternatives><name xml:lang="en"><surname>Skripkinа</surname><given-names>Nadezhda A.</given-names></name><name xml:lang="ru"><surname>Скрипкина</surname><given-names>Надежда Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>infectious disease specialist of the monoinfective hospital</p></bio><bio xml:lang="ru"><p>врач-инфекционист моноинфекционного госпиталя</p></bio><email>cytokines@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sizyakinа</surname><given-names>Ludmila P.</given-names></name><name xml:lang="ru"><surname>Сизякина</surname><given-names>Людмила Петровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>md, professor, head of the department of clinical immunology and allergology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, заведующая кафедрой клинической иммунологии и аллергологии</p></bio><email>msiziakina@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Antonova</surname><given-names>Elena A.</given-names></name><name xml:lang="ru"><surname>Антонова</surname><given-names>Елена Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p> head of laboratory research quality department</p></bio><bio xml:lang="ru"><p>начальник отдела качества лабораторных исследований</p></bio><email>cytokines@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sizyakin</surname><given-names>Dmitry V.</given-names></name><name xml:lang="ru"><surname>Сизякин</surname><given-names>Дмитрий Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>md, professor, professor of the department of urology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, профессор кафедры урологии</p></bio><email>cytokines@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zakurskayа</surname><given-names>Vita Ya.</given-names></name><name xml:lang="ru"><surname>Закурская</surname><given-names>Вита Яковлевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>assistant of the department of clinical immunology and allergology</p></bio><bio xml:lang="ru"><p>ассистент кафедры клинической иммунологии и аллергологии</p></bio><email>cytokines@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Semashko City Hospital No.1</institution></aff><aff><institution xml:lang="ru">Городская больница № 1 им. Н.А. Семашко</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Rostov State Medical University</institution></aff><aff><institution xml:lang="ru">Ростовский государственный медицинский университет</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-03-16" publication-format="electronic"><day>16</day><month>03</month><year>2022</year></pub-date><volume>19</volume><issue>1-4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>69</fpage><lpage>74</lpage><history><date date-type="received" iso-8601-date="2023-11-08"><day>08</day><month>11</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-11-08"><day>08</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Skripkinа N.A., Sizyakinа L.P., Antonova E.A., Sizyakin D.V., Zakurskayа V.Y.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Скрипкина Н.А., Сизякина Л.П., Антонова Е.А., Сизякин Д.В., Закурская В.Я.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Skripkinа N.A., Sizyakinа L.P., Antonova E.A., Sizyakin D.V., Zakurskayа V.Y.</copyright-holder><copyright-holder xml:lang="ru">Скрипкина Н.А., Сизякина Л.П., Антонова Е.А., Сизякин Д.В., Закурская В.Я.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2025-11-16"/></permissions><self-uri xlink:href="https://cijournal.ru/1684-7849/article/view/623115">https://cijournal.ru/1684-7849/article/view/623115</self-uri><abstract xml:lang="en"><p><bold>Objective:</bold> to study changes in innate and adaptive immunity in patients with a moderate course of COVID-19 with varying degrees of lung tissue damage. 40 patients with a moderate form of COVID-19 and varying degrees of damage to the lung tissue (up to 25% and up to 50%) and 30 patients from the control group (healthy donors) were examined using methods: computed tomography of the lungs, evaluation of a complete blood count, biochemical parameters, immunological studies, statistical. Differences in all patients with the control group consisted in a decrease in the absolute content of lymphocytes, in a significant increase in the relative content of natural killers and cytokine imbalance. The most significant differences were registered in the content of IL-6, depending on the degree of damage to the lung tissue. A smaller area of lung damage reflects a milder course of the disease, which does not exclude the need for dispensary observation and rehabilitation after discharge.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель:</bold> изучить изменения врожденного и адаптивного иммунитета у пациентов со среднетяжелым вариантом течения COVID-19 при различной степени поражения легочной ткани. Были обследованы 40 пациентов со среднетяжелой формой инфекции СOVID-19 и различной степенью поражения легочной ткани (до 25 % и до 50 %) и 30 пациентов из группы контроля (здоровые доноры) с применением методов: компьютерная томография легких, оценка общего анализа крови, биохимических показателей, иммунологические исследования, статистический. Отличия у всех пациентов с группой контроля заключались в уменьшении абсолютного содержания лимфоцитов, в значимом росте относительного содержания натуральных киллеров и цитокиновом дисбалансе. Наиболее существенные различия были зарегистрированы в содержании ИЛ-6 в зависимости от степени поражения легочной ткани. Меньшая площадь поражения легких отражает более легкое течение заболевания, что не исключает необходимости диспансерного наблюдения и реабилитации после выписки.</p></trans-abstract><kwd-group xml:lang="en"><kwd>coronavirus infection</kwd><kwd>COVID-19</kwd><kwd>computed tomography</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>коронавирусная инфекция</kwd><kwd>COVID-19</kwd><kwd>компьютерная томография</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Никифоров В.В., Суранова Т.Г., Чернобровкина Т.Я., Янковская Я.Д., Бурова С.В. Новая коронавирусная инфекция (Covid-19): клинико-эпидемиологические аспекты // Архивъ внутренней медицины. – 2020. – № 10 (2 (52)). – С. 87-93. Nikiforov V.V., Suranova T.G., Chernobrovkina T.Ya., Yankovskaya Y.D., Burova S.V. New coronavirus infection (Covid-19): clinical and epidemiological aspects // Archives of Internal Medicine. 2020. Vol.10 (2 (52)). P. 87-93.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Сизякина Л.П., Закурская В.Я., Скрипкина Н.А., Антонова Е.А. Уровень ферритина как предиктор тяжелого течения COVID-19 // Иммунология. – 2021. – Т. 42 (5). – С. 518–525. Siziakina L.P., Zakurskaya V.Ya., Skripkina N.A., Antonova E.A. Ferritin level as a predictor of severe COVID-19 // Immunology. 2021; Vol. 42 (5). P. 518–525.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Сизякина Л.П., Закурская В. Я., Скрипкина Н.А., Антонова Е.А., Сизякин Д.В. Клинико-иммунологическая характеристика среднетяжелых форм COVID-19 при различных уровнях маркера тканевой деструкции – лактатдегидрогеназы // Медицинский вестник Юга России. – 2021. – Т.12(4). – С. 108-115. Siziakina L.P., Zakurskaya V.Ya., Skripkina N.A., Antonova E.A., Sizyakin D.V. Clinical and immunological characteristics of moderate forms of COVID-19 at different levels of tissue destruction marker - lactate dehydrogenase // Medical Bulletin of the South of Russia. 2021; Vol.12(4), P.108-115.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Fara A., Mitrev Z., Rosalia R.A., Assas B.M. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines// Open Biology. 2020. Vol. 10(9) P 200160.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Han H., Ma Q., Li C., Liu R., Zhao L., Wang W., Zhang P., Liu X., Gao G., Liu F., Jiang Y., Cheng X., Zhu C., Xia Y. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors// Emerging microbes &amp; infections. 2020. Vol. 9(1), P. 1123–1130.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Hernández-Ruiz M., Zlotnik A. Mucosal Chemokines// Journal of interferon &amp; cytokine research. 2017. Vol. 37(2), P. 62–70.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Hu B., Huang S., Yin L. The cytokine storm and COVID-19// J Med Virol. 2021. Vol. 93(1), P. 250-256.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Luo X. H., Zhu Y., Mao J., Du R. C. T cell immunobiology and cytokine storm of COVID-19// Scandinavian journal of immunology. 2021. Vol. 93(3), e12989.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Machado-Carvalho L, Roca-Ferrer J, Picado C. IL-4/IFN-γ inflammatory cytokine profile induces a deficient regulation of the IL-1β/IL-1RI/EP2/COX-2 pathway in nasal mucosa // Respiratory medicine. 2019. Vol. 150, P.136-140.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Ochani, R., Asad, A., Yasmin, F., Shaikh S., Khalid H., Batra S., Sohail M. R., Mahmood S. F., Ochani R., Hussham Arshad M., Kumar A., Surani S. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management// Le infezioni in medicina. 2021. Vol. 29(1), P. 20–36.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Patterson B. K., Guevara-Coto J., Yogendra R., Francisco E. B., Long E., Pise A., Rodrigues H., Parikh P., Mora, J., Mora-Rodríguez R. A. Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning //Frontiers in immunology. 2021. Vol. 12.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Vallejo A., Vizcarra P., Quereda C., Moreno A., Casado J.L.; CoVEX study group. IFN-γ+ cell response and IFN-γ release concordance after in vitro SARS-CoV-2 stimulation// European journal of clinical investigation. 2021, Vol. 51(12), P.13636.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Zheng Y., Wang L., Ben S. Meta-analysis of chest CT features of patients with COVID-19 pneumonia // Journal of medical virology/ 2021/ Vol. 93,1, P. 241-249.</mixed-citation></ref></ref-list></back></article>
